Global Complement-Targeted Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Indication;

Paroxysmal Nocturnal Haemoglobinuria and Atypical Haemolytic Uraemic Syndrome (Ahus)

By Therapeutic Area;

Cardiovascular, Genetic, Hematological and Vascular, Infectious, Neurological, and Neuromuscular Disorders

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn666482069 Published Date: June, 2025 Updated Date: July, 2025

Complement-Targeted Therapeutics Market Overview

Complement-Targeted Therapeutics Market (USD Million)

Complement-Targeted Therapeutics Market was valued at USD 3988.35 million in the year 2024. The size of this market is expected to increase to USD 9797.52 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 13.7%.


Global Complement-Targeted Therapeutics Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 13.7 %


Study Period2025 - 2031
Base Year2024
CAGR (%)13.7 %
Market Size (2024)USD 3988.35 Million
Market Size (2031)USD 9797.52 Million
Market ConcentrationLow
Report Pages322
3988.35
2024
9797.52
2031

Major Players

  • Creative Biolabs
  • Complement UK
  • Novartis AG
  • Alexion Pharmaceuticals, Inc
  • Merck & Co., Inc
  • Pfizer Inc
  • Allergan plc
  • AbbVie

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Complement-Targeted Therapeutics Market

Fragmented - Highly competitive market without dominant players


The Complement-Targeted Therapeutics Market is expanding rapidly as immune-based disorders demand more precise and effective treatment strategies. Targeting the complement cascade has become critical for managing complex diseases such as atypical hemolytic uremic syndrome and autoimmune conditions. With more than 45% of immunology research now addressing complement-related mechanisms, this pathway is at the forefront of drug innovation.

Biologic Advancements Enhance Drug Efficacy
Recent advances in biologic therapies and genetic engineering have significantly improved the development of complement inhibitors. These cutting-edge approaches offer greater selectivity and lower side effect profiles. Around 38% of pipeline immunotherapies now include complement intervention as a core mechanism, underlining the sector’s momentum.

Clinical Research Drives Therapeutic Expansion
The surge in clinical research surrounding complement-modulating therapies is reinforcing product development. Over 30% of newly launched immunology trials globally are exploring complement-targeted solutions. This increased activity is enhancing treatment accessibility and speeding up product commercialization.

Collaborative Innovation Boosts Market Readiness
Collaborative efforts across biotech companies and academic institutions are also playing a crucial role. About 42% of recent immunology research partnerships have prioritized complement biology, fostering rapid advancements in drug development and market readiness for complement-based solutions.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Indication
    2. Market Snapshot, By Distribution Channel
    3. Market Snapshot, By Region
  4. Complement-Targeted Therapeutics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Growing Aging Population
        2. Increasing Research Investments
        3. Expanding Applications in Autoimmune Diseases
      2. Restraints
        1. Limited Awareness and Diagnosis
        2. Potential Adverse Effects
        3. Availability of Alternative Therapies
      3. Opportunities
        1. Personalized Medicine
        2. Collaborations and Partnerships
        3. Technological Innovations
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Complement-Targeted Therapeutics Market, By Indication, 2021- 2031(USD Million)
      1. Paroxysmal Nocturnal Haemoglobinuria
      2. Atypical Haemolytic Uraemic Syndrome (Ahus)
    2. Complement-Targeted Therapeutics Market, By Distribution Channel, 2021- 2031(USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    3. Complement-Targeted Therapeutics Market, By Geography, 2021- 2031(USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Creative Biolabs
      2. Complement UK
      3. Novartis AG
      4. Alexion Pharmaceuticals, Inc
      5. Merck & Co., Inc
      6. Pfizer Inc
      7. Allergan plc
      8. AbbVie
  7. Analyst Views
  8. Future Outlook of the Market